StreetAlpha.app
Home › Stocks › PTHS

Pelthos Therapeutics Inc. (PTHS)

$6.38
▼ −8.73%
LAST CLOSE · NOV 20

Pelthos Therapeutics sells FDA approved prescription skin treatments for molluscum contagiosum and impetigo from its base in Durham, North Carolina. It last closed at $6.38 on Nov 20, down 8.73% on the day. The next earnings report for PTHS is expected around Thu, Mar 18, 2027. For the quarter ended Sep 2026, PTHS reported EPS of -$2.04 on revenue of $15.4M, with revenue up 107.9% from a year ago. Over its last 6 reports the stock moved an average of 5.7% the session after earnings. Over the last 12 months PTHS insiders bought $1000K of stock on the open market and sold $486K, according to SEC Form 4 filings.

AI Auto Pilots
Is PTHS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PTHS.

Key Stats

Last 12 months
Results
Revenue
$51.3M
Net income
−$78.0M
−152.2% margin
EPS (diluted)
−$23.90
Free cash flow
−$32.6M
−63.5% margin
Valuation
Market cap
$25.1M
3.9M shares
P/E
–
No P/E while losing money
Price to sales
0.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$17.7M
At Sep 30
Shareholder equity
−$6.2M
Shares outstanding
3.9M
At Nov 5
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2024: $0$0FY2024FY2025: $16.8M$16.8MFY2025

From PTHS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · Time not announced
Reported EPS
-$2.04
Quarter ended Sep 2026
Year ago EPS
-$5.30
Same quarter last year
Revenue
$15.4M
+107.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$3.15Dec '24Mar 2025: -$3.21Mar '25Jun 2025: -$5.29Jun '25Sep 2025: -$5.30Sep '25Dec 2025: -$8.12Dec '25Mar 2026: -$7.57Mar '26Jun 2026: -$6.62Jun '26Sep 2026: -$2.04Sep '26Latest -$2.04
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $7.4MSep '25Dec 2025: $9.4MDec '25Mar 2026: $10.9MMar '26Jun 2026: $15.6MJun '26Sep 2026: $15.4MSep '26Latest $15.4M
How PTHS moved after its last 6 reports
Average move the session after a report ±5.7%
Nov 12, 2026Time not announced−14.5%
Aug 13, 2026Time not announced+0.1%
May 14, 2026Time not announced+6.5%
Mar 19, 2026Time not announced−4.6%
Nov 13, 2025Time not announced−7.3%
Aug 18, 2025Time not announced+1.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PTHSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PTHS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PTHS

Technical Analysis

PTHS · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 57% below its 20 day and 159% below its 50 day average. It is 261% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $6.10, and the nearest resistance the Pivot at $6.66.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 22.6%/day
Key levels
$32.5152 week high+409.6%
$23.02200 day average+260.8%
$21.44100 day average+236.1%
$20.50Swing high (Oct 30)+221.3%
$16.5250 day average+158.9%
$10.0020 day average+56.7%
$6.93Pivot R1+8.6%
$6.66Pivot+4.4%
$6.38Last close
$6.10Pivot S1−4.4%
$6.0252 week low−5.6%
Indicators
RSI (14)23.90Oversold below 30Oversold
MACD-3.06Above its signal lineBullish
Stochastic10.3Near the bottom of its rangeOversold
ADX (14)48.2Strong downtrend
Williams %R-93.4Oversold below −80, overbought above −20Oversold
CCI (20)-95.7Oversold below −100, overbought above 100Neutral
Rate of change−31.8%Change over 10 sessionsBearish
ATR (14)$1.44Typical daily range, 22.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PTHS

What happened before

See how PTHS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for PTHSHow many large options trades hit PTHS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PTHS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲19 buying vs 8 selling
  • ▲Held by funds +0.8 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2924+20.8%
In funds' top 10110.0%
Held by funds35.5%34.6%+0.8 pts
New / increased6 / 1310 / 7+11.8%
Reduced / sold out7 / 12 / 3+60.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PTHS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PTHS Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$1000K1 buy · 1 insider
Sold$486K13 sales · 5 insiders
34% of the selling was under pre-arranged trading plans.
2026-04 sold $57K2026-05 sold $40K2026-06 bought $1000K2026-06 sold $8K2026-07 sold $56K2026-10 sold $45KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 2Matthew PaulsDirectorSale plan786$21.00$17K
Oct 2Ezra M FriedbergDirectorSale plan558$20.72$12K
Oct 2Peter GreenleafDirectorSale plan797$21.17$17K
Jul 2Peter GreenleafDirectorSale plan797$26.13$21K
Jul 2Matthew PaulsDirectorSale plan786$26.16$21K
Jul 2Ezra M FriedbergDirectorSale plan558$26.09$15K
Every insider buy and sale for PTHS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PTHS insider trades →

From SEC Form 4 filings by PTHS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTHS is in one of them and how their past PTHS trades turned out.

PTHS in the AI portfolios
Loading…

PTHS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PTHS in an article yet. Here's the latest on the wider market.

PTHS in the news

About Pelthos Therapeutics

Pelthos Therapeutics is a biopharmaceutical company based in Durham, North Carolina. It sells prescription skin treatments that have been approved by the U.S. Food and Drug Administration. Its main products are ZELSUVMI, a topical gel for molluscum contagiosum, a common viral skin infection, and XEPI, a cream for impetigo, a bacterial skin infection. The products are used by patients, parents and caregivers, and are prescribed by dermatologists and pediatricians.

Headquarters
Durham, NC